Vyriad Inc. has announced the closing of a $25 million final tranche to its series B financing, bringing the total series B round to $85 million. This additional funding will support first-in-human testing of VV-169, Vyriad’s in vivo CAR T candidate, in patients with relapsed or treatment-refractory multiple myeloma.